220 related articles for article (PubMed ID: 22728874)
1. Deletion of IFNγ enhances hepatocarcinogenesis in FXR knockout mice.
Meng Z; Wang X; Gan Y; Zhang Y; Zhou H; Ness CV; Wu J; Lou G; Yu H; He C; Xu R; Huang W
J Hepatol; 2012 Nov; 57(5):1004-12. PubMed ID: 22728874
[TBL] [Abstract][Full Text] [Related]
2. Mice with hepatocyte-specific FXR deficiency are resistant to spontaneous but susceptible to cholic acid-induced hepatocarcinogenesis.
Kong B; Zhu Y; Li G; Williams JA; Buckley K; Tawfik O; Luyendyk JP; Guo GL
Am J Physiol Gastrointest Liver Physiol; 2016 Mar; 310(5):G295-302. PubMed ID: 26744468
[TBL] [Abstract][Full Text] [Related]
3. Hepatocarcinogenesis in FXR-/- mice mimics human HCC progression that operates through HNF1α regulation of FXR expression.
Liu N; Meng Z; Lou G; Zhou W; Wang X; Zhang Y; Zhang L; Liu X; Yen Y; Lai L; Forman BM; Xu Z; Xu R; Huang W
Mol Endocrinol; 2012 May; 26(5):775-85. PubMed ID: 22474109
[TBL] [Abstract][Full Text] [Related]
4. Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.
Sakurai T; Maeda S; Chang L; Karin M
Proc Natl Acad Sci U S A; 2006 Jul; 103(28):10544-51. PubMed ID: 16807293
[TBL] [Abstract][Full Text] [Related]
5. Induction of p53 renders ATM-deficient mice refractory to hepatocarcinogenesis.
Teoh N; Pyakurel P; Dan YY; Swisshelm K; Hou J; Mitchell C; Fausto N; Gu Y; Farrell G
Gastroenterology; 2010 Mar; 138(3):1155-65.e1-2. PubMed ID: 19919837
[TBL] [Abstract][Full Text] [Related]
6. NADPH Oxidase 1 in Liver Macrophages Promotes Inflammation and Tumor Development in Mice.
Liang S; Ma HY; Zhong Z; Dhar D; Liu X; Xu J; Koyama Y; Nishio T; Karin D; Karin G; Mccubbin R; Zhang C; Hu R; Yang G; Chen L; Ganguly S; Lan T; Karin M; Kisseleva T; Brenner DA
Gastroenterology; 2019 Mar; 156(4):1156-1172.e6. PubMed ID: 30445007
[TBL] [Abstract][Full Text] [Related]
7. Loss of immunity-supported senescence enhances susceptibility to hepatocellular carcinogenesis and progression in Toll-like receptor 2-deficient mice.
Lin H; Yan J; Wang Z; Hua F; Yu J; Sun W; Li K; Liu H; Yang H; Lv Q; Xue J; Hu ZW
Hepatology; 2013 Jan; 57(1):171-82. PubMed ID: 22859216
[TBL] [Abstract][Full Text] [Related]
8. Farnesoid X receptor inhibits gankyrin in mouse livers and prevents development of liver cancer.
Jiang Y; Iakova P; Jin J; Sullivan E; Sharin V; Hong IH; Anakk S; Mayor A; Darlington G; Finegold M; Moore D; Timchenko NA
Hepatology; 2013 Mar; 57(3):1098-106. PubMed ID: 23172628
[TBL] [Abstract][Full Text] [Related]
9. Activation of FXR modulates SOCS3/Jak2/STAT3 signaling axis in a NASH-dependent hepatocellular carcinoma animal model.
Attia YM; Tawfiq RA; Gibriel AA; Ali AA; Kassem DH; Hammam OA; Elmazar MM
Biochem Pharmacol; 2021 Apr; 186():114497. PubMed ID: 33675775
[TBL] [Abstract][Full Text] [Related]
10. Abberent expression of NOR1 protein in tumor associated macrophages contributes to the development of DEN-induced hepatocellular carcinoma.
Chen S; Zheng P; Wang W; Yi M; Chen P; Cai J; Li J; Peng Q; Ban Y; Zhou Y; Zeng Z; Li X; Xiong W; Li G; Xiang B
J Cell Physiol; 2018 Jun; 233(6):5002-5013. PubMed ID: 29227538
[TBL] [Abstract][Full Text] [Related]
11. Serine 727 phosphorylation of STAT3: an early change in mouse hepatocarcinogenesis induced by neonatal treatment with diethylnitrosamine.
Miyakoshi M; Yamamoto M; Tanaka H; Ogawa K
Mol Carcinog; 2014 Jan; 53(1):67-76. PubMed ID: 22911886
[TBL] [Abstract][Full Text] [Related]
12. Small heterodimer partner overexpression partially protects against liver tumor development in farnesoid X receptor knockout mice.
Li G; Kong B; Zhu Y; Zhan L; Williams JA; Tawfik O; Kassel KM; Luyendyk JP; Wang L; Guo GL
Toxicol Appl Pharmacol; 2013 Oct; 272(2):299-305. PubMed ID: 23811326
[TBL] [Abstract][Full Text] [Related]
13. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response.
Wang YD; Chen WD; Wang M; Yu D; Forman BM; Huang W
Hepatology; 2008 Nov; 48(5):1632-43. PubMed ID: 18972444
[TBL] [Abstract][Full Text] [Related]
14. DJ-1 promotes development of DEN-induced hepatocellular carcinoma and proliferation of liver cancer cells.
Qiu B; Wang J; Yu Y; Zhen C; Gu J; Liu W; Wen Y; Chen L; Gao Y; Xia Q; Kong X
Oncotarget; 2017 Jan; 8(5):8499-8511. PubMed ID: 28036277
[TBL] [Abstract][Full Text] [Related]
15. Hepatic loss of miR-122 predisposes mice to hepatobiliary cyst and hepatocellular carcinoma upon diethylnitrosamine exposure.
Hsu SH; Wang B; Kutay H; Bid H; Shreve J; Zhang X; Costinean S; Bratasz A; Houghton P; Ghoshal K
Am J Pathol; 2013 Dec; 183(6):1719-1730. PubMed ID: 24113455
[TBL] [Abstract][Full Text] [Related]
16. Mechanisms of STAT3 activation in the liver of FXR knockout mice.
Li G; Zhu Y; Tawfik O; Kong B; Williams JA; Zhan L; Kassel KM; Luyendyk JP; Wang L; Guo GL
Am J Physiol Gastrointest Liver Physiol; 2013 Dec; 305(11):G829-37. PubMed ID: 24091600
[TBL] [Abstract][Full Text] [Related]
17. Inhibitory role of Smad7 in hepatocarcinogenesis in mice and in vitro.
Wang J; Zhao J; Chu ES; Mok MT; Go MY; Man K; Heuchel R; Lan HY; Chang Z; Sung JJ; Yu J
J Pathol; 2013 Aug; 230(4):441-52. PubMed ID: 23625826
[TBL] [Abstract][Full Text] [Related]
18. Liver specific deletion of CYLDexon7/8 induces severe biliary damage, fibrosis and increases hepatocarcinogenesis in mice.
Urbanik T; Boger RJ; Longerich T; Becker K; Ehrenberg KR; Hövelmeyer N; Hahn M; Schuchmann M; Jäger D; Waisman A; Wörns MA; Schulze-Bergkamen H
J Hepatol; 2012 Nov; 57(5):995-1003. PubMed ID: 22728872
[TBL] [Abstract][Full Text] [Related]
19. The chemokine receptor CCR10 promotes inflammation-driven hepatocarcinogenesis via PI3K/Akt pathway activation.
Wu Q; Chen JX; Chen Y; Cai LL; Wang XZ; Guo WH; Zheng JF
Cell Death Dis; 2018 Feb; 9(2):232. PubMed ID: 29445190
[TBL] [Abstract][Full Text] [Related]
20. CXCR6 Inhibits Hepatocarcinogenesis by Promoting Natural Killer T- and CD4
Mossanen JC; Kohlhepp M; Wehr A; Krenkel O; Liepelt A; Roeth AA; Möckel D; Heymann F; Lammers T; Gassler N; Hermann J; Jankowski J; Neumann UP; Luedde T; Trautwein C; Tacke F
Gastroenterology; 2019 May; 156(6):1877-1889.e4. PubMed ID: 30710528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
